Cell therapy primed liver transplant patients to avoid organ rejection, small study shows

Also: A new study on younger adult colon cancer deaths and education level ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­ ­  

April 17, 2026 Check out STAT+

Sponsored By

By Angus Chen Cancer Reporter

Today’s a short newsletter day, as we are rolling quickly into AACR. I think this is going to be an exciting conference and, again, be sure to sign up for our AACR in 30 Seconds newsletter. The big news of the week in cancer was the positive phase 3 RASolute 302 trial from Rev Med, and we are expecting more data from them and others on RAS inhibitors. I’ve also got a story coming as well diving into the next generation of RAS inhibitors and takes a deep look at the significance of these medicines and the science behind them. Our live event, STAT@AACR is also this coming Tuesday in San Diego. Register here. Some guests include Robert Winn from VCU Massey, Greg Verdine from LifeMine Therapeutics, and Susan Galbraith from AstraZeneca. Looking forward to seeing you all in San Diego!

---

Mark Humphrey/AP STAT+ | Cell therapy primed liver transplant patients to avoid organ rejection, small study shows Cells from living donors were injected into patients before the transplant to prime their immune system to accept the new organ with less immunosuppression. By Elizabeth Cooney A pancreatic cancer breakthrough, and new hope for an off-the-shelf CAR-T treatment We dive into the biggest news of the week: Revolution Medicines and the stunning survival benefit reported for its experimental cancer drug. By Adam Feuerstein, Elaine Chen, and Allison DeAngelis STAT+ | New Bain biotech startup, building on BMS drugs, gets a name and a CEO Last summer, Bain Capital Life Sciences said it would form the startup, created with $300 million and five drugs licensed from Bristol Myers Squibb. By Allison DeAngelis Adobe STAT+ | HaloMD’s legal win highlights the difficulty of challenging arbitration decisions Courts set a high bar for overturning arbitration cases, a major challenge for lawsuits seeking to overturn No Surprises Act dispute decisions. By Tara Bannow

More around STAT

---

In other news Younger adult colon cancer deaths are concentrated in people with less education, study says, Associated Press Why I Decided to Share My Cancer Surgery With Times Readers, New York Times Researchers behind GLP-1 obesity drugs advance new approach: Drop GLP-1 as a target, STAT

---

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2026, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser